Chandran Geethan J, Mikler John R, Keegan David L
Department of General Surgery, University of Saskatchewan, Saskatoon, SK.
CMAJ. 2003 Sep 2;169(5):439-42.
We report a case involving an 81-tear-old man with schizoaffective disorder who presented with neuroleptic malignant syndrome (NMS) after an increase in his neuroleptic dose. NMS, a rare but potentially fatal complication of neuroleptic medications (e.g., antipsychotics, sedatives and antinauseants), is characterized by hyperthermia, muscle rigidity, an elevated creatine kinase level and autonomic instability. The syndrome often develops after a sudden increase in dosage of the neuroleptic medication or in states of dehydration. Treatment is mainly supportive and includes withdrawal of the neuroleptic medication and, possibly, administration of drugs such as dantrolene and bromocriptine. Complications of NMS include acute renal failure and acute respiratory failure. Given the widespread prescription of neuroleptics by physicians in a variety of fields, all physicians need to be able to recognize and appropriately manage NMS.
我们报告了一例病例，患者为一名81岁患有分裂情感性障碍的男性，在增加抗精神病药物剂量后出现了抗精神病药恶性综合征（NMS）。NMS是抗精神病药物（如抗精神病药、镇静剂和止吐药）罕见但可能致命的并发症，其特征为高热、肌肉强直、肌酸激酶水平升高和自主神经功能不稳定。该综合征常发生于抗精神病药物剂量突然增加或脱水状态下。治疗主要是支持性的，包括停用抗精神病药物，可能还需使用如丹曲林和溴隐亭等药物。NMS的并发症包括急性肾衰竭和急性呼吸衰竭。鉴于各领域医生广泛开具抗精神病药物处方，所有医生都需要能够识别并妥善处理NMS。
